Conversely, Galectin-7, significantly upregulated in lung squamous cell carcinoma (LUSC) versus LUAD, is validated by increased serum levels and higher immunohistochemistry (IHC) expression in LUSC, indicating its potential as a biomarker. Here, LGALS7 is linked to squamous cell lung carcinoma.